Author(s)

Kakil Ibrahim Rasul

National Center for Cancer Care and Research (NCCCR), Doha, Qatar.

Patients with HCC continue to have a dismal prognosis, with 1-year and 3-year survival rates of 36 and 17%, respectively. This is in part related to more than two-thirds of tumors being diagnosed at advanced stages, as well as a substantial portion of patients with early HCC failing to receive potentially curative treatments. Systemic therapy for advanced unresectable HCC limited until the discovery of sorafenib, we are reporting a 53 year patient with unresectable HCC achieved complete remission clinically, radiologically and biochemically with sorafenib which is the first case report.

Hepatocellular Ca; Sorafenib; Chemoembolization

Rasul, K. (2012) Can we achieve complete remission in locally advanced unresectable Hepatocellular Carcinoma (HCC) by using Sorafenib? Case report and review of literature from Qatar. Modern Chemotherapy, 1, 1-4. doi: 10.4236/mc.2012.11001.